張磊，主任醫(yī)師，博士研究生導(dǎo)師，長(zhǎng)期從事血液病臨床及基礎(chǔ)工作，在專業(yè)領(lǐng)域做出了一系列原創(chuàng)性成果。在NEJM，BMJ，Nat Med等國(guó)內(nèi)外知名期刊發(fā)表SCI論文百余篇，獲得國(guó)家發(fā)明專利8項(xiàng)。曾獲2009年度國(guó)家科技進(jìn)步二等獎(jiǎng)、2023年度天津市科學(xué)技術(shù)進(jìn)步一等獎(jiǎng)等國(guó)家級(jí)及省部級(jí)獎(jiǎng)項(xiàng)9項(xiàng)。獲得國(guó)家科技創(chuàng)新領(lǐng)軍人才、天津市杰出人才等項(xiàng)目資助。獲國(guó)務(wù)院政府特殊津貼專家、國(guó)家衛(wèi)生健康突出貢獻(xiàn)中青年專家等稱號(hào)。

長(zhǎng)期從事出凝血疾病以及基因治療方面的研究。牽頭開展亞洲首項(xiàng)血友病基因治療臨床試驗(yàn)，全球首次實(shí)現(xiàn)基因治療患者安全接受大手術(shù)，牽頭完成8項(xiàng)基因治療臨床研究，治愈百余名重癥血友病患者，并推動(dòng)中國(guó)首個(gè)血友病基因治療產(chǎn)品注冊(cè)試驗(yàn)進(jìn)入III期臨床；利用新型CD38單抗實(shí)現(xiàn)血小板減少癥的持續(xù)穩(wěn)定治愈。相關(guān)成果入選年度“中國(guó)十大醫(yī)學(xué)科技新聞”和“血液學(xué)十大研究進(jìn)展”等。在NEJM，BMJ，Nat Med等國(guó)際頂尖期刊發(fā)表SCI論文百余篇。培養(yǎng)博士、碩士、博士后30余名。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Xue F#, Ju M#, Zhu T#, Zhou Z#, Sun J, Yang L, Yan Z, Zhou H, Du X, Zheng C, Zheng J, Wu X, Du Z, Jiang W, Yang C, Xiao X, Liu W, Yang R, Zhang L*. Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. Nature Medicine. 2025 Nov 20. Online ahead of print. (IF=50.319, PIII)

2. Chen Y#, Xu Y#, Dai J#, Sun T#, Li H#, Hua Z#, Zhou Z, Zhou H, Yan Z, Zhao X, Xue F, Liu W, Liu X, Fu R, Wang W, Chi Y, Dong H, Ju M, Dai X, Gu W, Pei X, Yang R, Zhang L*. Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial. British Medical Journal. 2025 Oct 21;391:e084314. ( IF=42.7)

3. Sun T#, Chen Y#, Zhang L*. Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia. New England Journal of Medicine. 2025 May 29;392(20):2069-2071. (IF=96.2)

4. Chen Y#, Xu Y#, Li H#, Sun T#, Cao X#, Wang Y, Xue F, Liu W, Liu X, Dong H, Fu R, Dai X, Wang W, Ma Y, Song Z, Chi Y, Ju M, Gu W, Pei X, Yang R, Zhang L*. A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia. New England Journal of Medicine. 2024 Jun 20;390(23):2178-2190. (IF=96.2)

5. Chen Y#, Xu Y#, Chi Y#, Sun T#, Gao Y#, Dou X, Han Z, Xue F, Li H, Liu W, Liu X, Dong H, Fu R, Ju M, Dai X, Wang W, Ma Y, Song Z, Gu J, Gong W, Yang R, Zhang L*. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduction and Targeted Therapy. 2024 Apr 23;9(1):102. (IF=40.8)

6. Zhang L#*. Gene therapy in China: past, present, and future. Lancet Haematology. 2022 Dec;9(12):e869-e871. (IF=24.7)

7. Xue F#, Wang P#, Yuan Z#, Shi C, Fang Y, Liu W, Wang Y, Xiao X, Yang R, George LA, Zhang L*. Total Knee Arthroplasty after Gene Therapy for Hemophilia B. New England Journal of Medicine. 2022 Oct 27;387(17):1622-1624. (IF=158.5)

8. Xue F#, Li H#, Wu X#, Liu W#, Zhang F, Tang D, Chen Y, Wang W, Chi Y, Zheng J, Du Z, Jiang W, Zhong C, Wei J, Zhu P, Fu R, Liu X, Chen L, Pei X, Sun J, Cheng T, Yang R*, Xiao X*, Zhang L*. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematology. 2022 Jul;9(7):e504-e513. (IF=24.7)

9. Tong J#, Sun T#, Ma S#, Zhao Y#, Ju M#, Gao Y, Zhu P, Tan P, Fu R, Zhang A, Wang D, Wang D, Xiao Z, Zhou J, Yang R, Loughran SJ, Li J, Green AR, Bresnick EH, Wang D, Cheng T*, Zhang L*, Shi L*. Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell Stem Cell. 2021 Mar 4;28(3):502-513.e6. (IF=25.269)

10. Jiang H, Yu Z, Ding N, Yang M, Zhang L, Fan X, Zhou Y, Zou Q, Hou J, Zheng J, Zhang L*, Xu Y*, Liu J*. The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. 2020 Jul 2;136(1):119-129. (IF=22.113)